Table 4. Treatment Outcomes for NVE and NVD at 12 and 52 Weeks.
| Outcome | Eyes, No./total No. (%) at 12 wk | Eyes, No./total No. (%) at 52 wk | ||||||
|---|---|---|---|---|---|---|---|---|
| NVD | NVE | Difference, % (95% CI)a | P value | NVD | NVE | Difference, % (95% CI)a | P value | |
| Regression | 16/43 (37.2) | 83/102 (81.4) | 97.6 (94.4 to 100) | <.001 | 23/43 (53.5) | 89/102 (87.3) | 29.0 (−9.6 to 67.6) | .04 |
| New occurrence | 1/78 (1.3) | 14/119 (11.8) | −15.8 (−24.0 to −7.6) | .67 | 4/78 (5.1) | 35/119 (29.4) | 47.8 (−6.3 to 100) | .05 |
| Persistence | 19/35 (54.3) | 28/100 (28.0) | 5.8 (−33.3 to 44.9) | .78 | 20/39 (51.3) | 29/100 (29.0) | −10.3 (−40.0 to 19.4) | .52 |
Abbreviations: NVD, disc neovascularization; NVE, neovascularization elsewhere.
a
The Pearson χ2 test was used to compare NVD with NVE.